You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 5,716,794

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,716,794

Title:	Celiac antigen
Abstract:	In this invention a novel antigen is provided for screening patients suspected of having celiac disease. The antigen is prepared by starting with human placenta tissue which is perfused with a herpes and collagenase buffer to obtain a signle cell suspension. This suspension is enriched to obtain an enriched protein portion and then separated out to obtain an embryonic celiac antigen (ECA). This ECA is used with serum from patients to effect binding of ECA with IgA in the serum while applying a human IgA antibody to the serum. The results are then read on a spectrophotometer to confirm or negate the presence of celiac disease.
Inventor(s):	Tjota; Amin (Williamsville, NY)
Assignee:	Xybernaut Corporation (Fairfax, VA)
Application Number:	08/626,243
Patent Claims:	1. A method for the isolation of an antigen from human placenta tissue to be used as a screening assay for celiac disease comprising: a) cleaning and washing said placenta tissue with HEPES buffer; b) digesting the said placenta tissue with collagenase buffer to obtain a placenta cell population in suspension, said placenta cell population containing cytotrophoblast cells; c) enriching the cytotrophoblast cell population in said suspension via a 0-30% discontinuous Percoll gradient; d) extracting protein from said enriched cytotrophoblast cells with lysing buffer, extraction buffer and via ultracentrifugation to obtain a protein portion; e) isolating embryonic celiac antigen (ECA) from said extracted protein by applying said protein portion to an ion exchange DEAE Sephadex column followed by size exclusion gel chromatography; and f) identifying by SDS-PAGE and western blotting embryonic celiac antigens comprising protein molecules with an isoelectric range (pI) of from 5.1-5.8 and an apparent molecular weight selected from the group consisting of 55 kd, 65 kd, and 110 kd.

Details for Patent 5,716,794

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.